Benzinga | Aug 11, 2021 08:05AM EDT

IN8bio Completes Dosing Of First Cohort In Phase 1 Clinical Trial With Allogeneic Gamma Delta T-Cell Therapy In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced completion of dosing of the first patient cohort in a Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant (HSCT). The three patients comprising the first cohort did not experience any severe adverse infusion reactions or dose limiting toxicities (DLTs) to date. The first two patients are at 14.5 months and 12.2 months, respectively, post-HSCT as of June 30, 2021, and continue to be in complete remission.